Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Minerva Neurosciences (Nasdaq:NERV), a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
CEO Remy Luthringer will join a fireside chat on June 4 at 4:20 PM ET, with a live webcast and a 90-day replay available.
Positive
- None.
Negative
- None.
News Market Reaction – NERV
In the May 19 session, NERV declined 8.02%, reflecting a notable negative market reaction. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.4x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-05-05 | Earnings and update | Neutral | -1.3% | Q1 2026 results and Phase 3 trial initiation details for roluperidone. |
| 2026-04-02 | Leadership change | Neutral | -0.9% | Appointment of new Chief Business Officer and General Counsel and executive transition. |
| 2026-03-31 | Phase 3 trial start | Positive | -7.0% | First patient screened in global confirmatory Phase 3 trial of roluperidone. |
| 2026-03-25 | Safety data update | Positive | +0.7% | Open‑label safety data for roluperidone with olanzapine showing no significant adverse effects. |
| 2026-03-12 | Conference participation | Neutral | +5.3% | Announcement of presentation at The Stifel 2026 Virtual CNS Forum. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamental and clinical updates often saw modest or negative next-day moves, while prior conference participation once coincided with a short-term gain.
Over the past few months, Minerva has focused on advancing roluperidone, including screening the first patient in its global confirmatory Phase 3 trial and presenting favorable open‑label safety data showing no clinically significant adverse effects when co‑administered with olanzapine. Q1 2026 results highlighted a GAAP net loss of $125.4M driven by warrant liability changes but ended with $78.2M in cash and equivalents. The company also announced leadership changes and previously participated in a virtual CNS forum, making the new Jefferies conference appearance part of an ongoing investor outreach pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
| 2026 Jefferies Global Healthcare Conference | |
| Format: | Fireside chat |
| Day/Time: | Thursday, June 4 at 4:20 PM ET |
| Webcast: | Link here |
If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
